Baxter, M.A., Glen, H. and Evans, T.R.J. (2018) Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Future Oncology, 14(20), pp. 2021-2029. (doi: 10.2217/fon-2017-0689) (PMID:29783903)
|
Text
159272.pdf - Accepted Version 795kB |
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for approximately 90% of cases. Patients often present at an advanced stage when treatment options are limited. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been the first-line treatment in this setting for almost a decade. Several subsequent targeted therapies have failed to demonstrate significant improvement in survival. The results of the REFLECT study suggest that lenvatinib, a multikinase inhibitor, may have promised as a first-line treatment in patients with advanced HCC. This article will review the development of lenvatinib and the evidence behind its potential use in patients with advanced HCC.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Glen, Dr Hilary and Evans, Professor Jeff |
Authors: | Baxter, M.A., Glen, H., and Evans, T.R.J. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Future Oncology |
Publisher: | Future Medicine |
ISSN: | 1479-6694 |
ISSN (Online): | 1744-8301 |
Published Online: | 22 May 2018 |
Copyright Holders: | Copyright © 2018 Future Medicine Ltd |
First Published: | First published in Future Oncology 14(20): 2021-2029 |
Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record